Free Trial

PDS Biotechnology (PDSB) Competitors

PDS Biotechnology logo
$1.30 -0.02 (-1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 -0.01 (-0.38%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDSB vs. INZY, TNXP, LIMN, CADL, PVLA, DBVT, SGMT, IMMP, ACB, and NGNE

Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Inozyme Pharma (INZY), Tonix Pharmaceuticals (TNXP), Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Aurora Cannabis (ACB), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.

PDS Biotechnology vs. Its Competitors

PDS Biotechnology (NASDAQ:PDSB) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

PDS Biotechnology's return on equity of -150.59% beat Inozyme Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
PDS BiotechnologyN/A -150.59% -69.15%
Inozyme Pharma N/A -159.93%-82.48%

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 592.31%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 193.75%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, research analysts clearly believe PDS Biotechnology is more favorable than Inozyme Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PDS Biotechnology
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Inozyme Pharma
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44

PDS Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

In the previous week, PDS Biotechnology and PDS Biotechnology both had 4 articles in the media. Inozyme Pharma's average media sentiment score of 0.64 beat PDS Biotechnology's score of -0.09 indicating that Inozyme Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PDS Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inozyme Pharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by company insiders. Comparatively, 12.2% of Inozyme Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Inozyme Pharma is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDS BiotechnologyN/AN/A-$37.61M-$0.94-1.38
Inozyme PharmaN/AN/A-$102.02M-$1.69-2.37

Summary

PDS Biotechnology beats Inozyme Pharma on 8 of the 13 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PDSB vs. The Competition

MetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$60.34M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-1.388.0519.5820.23
Price / SalesN/A296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book2.557.748.085.60
Net Income-$37.61M-$54.96M$3.16B$248.43M
7 Day Performance-2.69%6.04%3.77%5.15%
1 Month Performance-22.62%4.47%3.90%7.62%
1 Year Performance-63.07%6.12%34.22%21.56%

PDS Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDSB
PDS Biotechnology
2.0045 of 5 stars
$1.30
-1.5%
$9.00
+592.3%
-60.8%$60.34MN/A-1.3820News Coverage
Gap Up
INZY
Inozyme Pharma
3.4574 of 5 stars
$4.00
+0.3%
$11.75
+193.8%
N/A$257.60MN/A-2.3750
TNXP
Tonix Pharmaceuticals
2.6223 of 5 stars
$35.98
+3.1%
$585.00
+1,525.9%
-36.3%$256.69M$10.09M-0.0250Trending News
LIMN
Liminatus Pharma
N/A$11.15
+17.6%
N/AN/A$246.62MN/A0.00N/AGap Up
CADL
Candel Therapeutics
2.4772 of 5 stars
$5.06
+3.3%
$22.00
+334.8%
+2.9%$245.50M$120K-3.7860News Coverage
PVLA
Palvella Therapeutics
2.6219 of 5 stars
$22.54
+2.1%
$46.29
+105.3%
N/A$244.11M$42.81M-1.86N/A
DBVT
DBV Technologies
3.6074 of 5 stars
$9.16
+3.2%
$14.75
+61.0%
+181.7%$243.22M$4.15M-1.8680Gap Down
SGMT
Sagimet Biosciences
1.9939 of 5 stars
$7.62
-3.2%
$26.60
+249.1%
+203.5%$241.41M$2M-4.338
IMMP
Prima BioMed
1.0033 of 5 stars
$1.64
flat
$7.00
+326.8%
-14.6%$239.50M$5.14M0.002,021Positive News
ACB
Aurora Cannabis
0.3488 of 5 stars
$4.24
+2.2%
N/A-14.6%$233.29M$246.72M38.551,130
NGNE
Neurogene
3.5796 of 5 stars
$14.95
-7.5%
$46.17
+208.8%
-44.5%$230.48M$930K-3.4490

Related Companies and Tools


This page (NASDAQ:PDSB) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners